FDA approves Merck pneumococcal vaccine for high-risk children and teens

• Capvaxive protects against multiple strains of Streptococcus pneumoniae bacteria, which can cause pneumonia, meningitis, and blood infections
• Approval was based on a late-stage trial of 874 participants where Capvaxive matched or outperformed PPSV23, an older pneumococcal vaccine
• The vaccine is administered as a single dose and complements existing childhood pneumococcal vaccines; it was previously approved for adults in June 2024

FDA Approves Merck's Capvaxive for High-Risk Pediatric Patients

Merck & Co. announced Thursday that the U.S. Food and Drug Administration has approved expanded use of its pneumococcal vaccine Capvaxive for high-risk children and teenagers aged 2-17.

Key Details:

The approval targets patients who have completed standard childhood pneumococcal vaccination schedules but face elevated infection risk due to chronic conditions including heart disease, lung disease, kidney disease, liver disease, or diabetes. Capvaxive protects against multiple strains of Streptococcus pneumoniae bacteria, which causes serious illnesses including pneumonia, meningitis, and blood infections.

The vaccine was initially approved for adults in June 2024, making this pediatric expansion a significant market extension. It is administered as a single dose to complement existing childhood pneumococcal vaccines.

Clinical Data:

The expanded approval was based on a late-stage trial involving 874 participants. Results showed Capvaxive matched or outperformed PPSV23, an older pneumococcal vaccine, with generally short-lived side effects.

Market Context:

Pneumococcal disease spreads through respiratory secretions and poses particular risk to children under five and adults over 50. The disease transmission occurs through contact with saliva or mucus, making vaccination crucial for vulnerable populations.

Implications:

This approval expands Merck's addressable market for Capvaxive into the pediatric high-risk segment, potentially driving revenue growth beyond the adult population. The vaccine fills a critical need for children with chronic conditions who require additional protection despite completing standard vaccination schedules. This development strengthens Merck's position in the vaccine market and addresses an underserved medical need in pediatric infectious disease prevention.